|
VAL-413 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Orotecan®
San Francisco, California1 trial
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
UCSF, Mission Bay - Benioff Children's Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.